Urology and Gynaecology

REVIEWS AND EXPERT REPORTS

Extract of Serenoa repens: Prostaserene®. Treatment for benign prostatic hyperplasia, Drugs of the Future, 19(5), 452-453, (1994).

Nonclinical and Clinical Overviews of Cyproterone acetate 50 mg, CTD Modules 2.4 and 2.5.

Nonclinical and Clinical Overviews of Cyproterone acetate 2 mg / Ethinylestradiol 0.035 mg, CTD Modules 2.4 and 2.5.

Nonclinical and Clinical Overviews of Nomegestrol acetate, CTD Modules 2.4 and 2.5.

Nonclinical and Clinical Overviews of Folic Acid, CTD Modules 2.4 and 2.5.

Nonclinical and Clinical Overviews of Desogestrel/Ethinylestradiol, CTD Modules 2.4 and 2.5.

Nonclinical and Clinical Overviews of Gestoden/Ethinylestradiol, CTD Modules 2.4 and 2.5.

CLINICAL TRIALS

Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia : an open multicentre study, European Journal of Clinical Research, 9, 47-57, (1997).

A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate, European Journal of Clinical Research, 9, 247-259, (1997).

Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms, Phytotherapy Research, 11, 558-563, (1997).